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Exogenousadministrationofisletamyloidpolypeptide(IAPP)hasbeenshowntoinhibitbothinsulinandglucagonsecretion.This
study examined α-cell function in mice with β-cell speciﬁc overexpression of human IAPP (hIAPP) after an oral protein gavage
(75mg whey protein/mouse). Baseline glucagon levels were higher in transgenic mice (41±4.0pg/mL, n = 6) than in wildtype
animals (19±5.1pg/mL, n = 5, P = .015). In contrast, the glucagon response to protein was impaired in transgenic animals
(21±2.7pg/mL in transgenic mice versus 38±5.7pg/mL in wildtype mice at 15 minutes; P = .027). Baseline insulin levels did not
diﬀer between the groups, while the insulin response, as the glucagon response, was impaired after protein challenge (P = .018).
G l u c o s el e v e l sw e r en o td i ﬀerent between the groups and did not change signiﬁcantly after protein gavage. Acetaminophen was
given through gavage to the animals (2mg/mouse) to estimate gastric emptying. The plasma acetaminophen proﬁle was similar
in the two groups of mice. We conclude that disturbances in glucagon secretion exist in mice with β-cell speciﬁc overexpression of
human IAPP, which are not secondary to changes in gastric emptying. The reduced glucagon response to protein challenge may
reﬂect a direct inhibitory inﬂuence of hIAPP on glucagon secretion.
Copyright © 2008 B. Ahr´ en and M. S¨ orhede Winzell. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Islet amyloid polypeptide is a 37-amino-acid peptide, which
is produced in the β-cells in the pancreatic islets [1–3]. It is
coreleased with insulin [4], and exogenous administration of
IAPP inhibits insulin secretion [2, 3, 5–7]. Several studies
have also shown that exogenous administration of IAPP at
supraphysiological doses inhibits glucagon secretion [8–11].
IAPP of the human form may lead to ﬁbril formation, which
causes amyloid deposition in the islets resulting in β-cell
dysfunctionanddiabetes[12–14].Wehavepreviouslyshown
that mice with β-cell speciﬁc overexpression of the human
form of IAPP (hIAPP) have defective insulin secretion and
disturbed islet topography with centrally located glucagon
producing α-cells [15, 16]. Whether these mice in addition
have disturbed glucagon secretion is, however, not known.
Therefore, the aim of the present study was to examine the
glucagon response to an oral protein load in these mice
compared to wildtype mice. Since IAPP has been shown to
inhibit gastric emptying [11], also the gastric emptying rate
in the transgenic and wildtype mice was evaluated with the
previously described acetaminophen-test [17], to control for
any diﬀerences in gastric emptying between the groups.
2. METHODS
2.1. Animals
Hemizygous transgenic mice with islet β-cell expression of
hIAPP on a C57BL/6J/6xDBA/2 background were gener-
ated as previously described [18]. Transgenic status was
determined by PCR using oligonucleotide primers directed
against the hIAPP transgene [19]. The transgenic mice and
their wildtype controls were kind gifts of Dr Steven E Kahn,
University of Washington, Seattle, Wash, USA. Transgenic
and wildtype mice were transported from the animal facility
of the University of Washington, Seattle, to the In Vivo
Department, Biomedical Center, Lund University, Lund,
Sweden, after embryo transfer performed at Taconic A/S, Ry,
Denmark. The animals were cross-bred for >16 generations
to C57BL/6J mice. The animals were kept in a 12-hour light2 Experimental Diabetes Research
schedule (lights on at 0600am) and given a standard pellet
diet (fat 11.4%, carbohydrate 62.8%, protein 25.8% on an
energy base, total energy 12.6kJ/g) and tap water ad libitum.
The Ethics Committee in Lund/Malm¨ o approved the study.
2.2. Experiments
Following a four-hour period after removal of food from
the cage, female transgenic and wildtype animals were
anesthetized with an intraperitoneal injection of midazo-
lam (Dormicum, Hoﬀman-La-Roche, Basel, Switzerland,
0.2mg/mouse) as well as a combination of ﬂuanison
(0.4mg/mouse) and fentanyl (0.02mg/mouse; Hypnorm,
Janssen, Beerse, Belgium). Thirty minutes later, a blood
samplewastakenfromtheretrobulbar,intraorbital,capillary
plexus in heparinized tubes. Then, whey protein (100%
Anywhey, 75mg, Optimum Nutrition, Lindesberg, Sweden)
and acetaminophen (paracetamol; Sigma Chemical Co, St
Louis, Mo, 2mg) dissolved in saline (total volume 500μL)
were administered through a gastric tube (outer diameter
1.2mm). After 15, 30, 60, and 120 minutes, blood samples,
75μL each, were collected. Blood was kept in heparinized
tubes containing 5μL Trasylol (aprotinin; 10000KIE/mL;
Bayer HealthCare AG, Leverkusen, Germany), immediately
centrifuged whereupon plasma was separated and stored
at −20◦C until analysis for glucose, glucagon, insulin, and
acetaminophen.
2.3. Analyses
Plasma glucagon was determined with radioimmunoassay
(Linco Res, St Charles, Mo, USA) with a guinea pig
antiglucagon antibody, radioiodine labelled glucagon as
tracer and glucagon standard. CV of the assay is 8% and
the sensitivity of the assay is 10pg/mL. The antibodies do
not cross-react with GLP-1. Plasma insulin was determined
with radioimmunoassay (Linco) with a guinea pig antirat
insulin antibody, radioiodine labelled human insulin as
tracer and rat insulin as standard. Plasma acetaminophen
was determined with a colorimetric assay (Cambridge Life
Science, Ely, Cambridgeshire, UK). Plasma glucose was
determined with the glucose oxidase method.
2.4. Calculationsandstatistics
Means ±SEM are shown. Statistical comparisons were per-
formed with the Student’s t-test. For estimation of glucagon
secretion, the increase in plasma glucagon levels during
the ﬁrst 15 minutes after protein gavage was estimated by
subtracting baseline glucagon values from the 15-minute
glucagon values. The area under the glucagon and insulin
curves (AUCs) were also calculated using the trapezoid rule.
3. RESULTS
3.1. Glucagonresponsetooralprotein
Figure 1 (upper left panel) shows plasma glucagon levels
during the oral protein challenge. Baseline glucagon levels
were higher in the transgenic animals (41 ± 4.0pg/mL, n =
6) than in the wildtype animals (19 ± 5.1pg/mL, n = 5,
P = .015). Glucagon levels at 15, 30, and 60 minutes after
protein administration did not diﬀer signiﬁcantly between
the groups, whereas the levels after 120 minutes were, again,
signiﬁcantly, higher in the transgenic animals (P = .008).
Glucagon secretion was estimated as the change in glucagon
levels during the ﬁrst 15 minutes after protein gavage. This
15-minute glucagon response to protein administration was
impaired in the transgenic animals, being 21 ± 2.7pg/mL
in transgenic mice versus 38 ± 5.7pg/mL in wildtype mice
(P = .027). The suprapasal AUC for glucagon for the entire
120-minute study period did not diﬀer signiﬁcantly between
the groups, being 4.3±1.1μg/mL × 120 minutes in wildtype
mice versus 3.9 ± 0.9μg/mL × 120 minutes in transgenic
mice.
3.2. Insulinandglucoseresponsestooralprotein
Baseline insulin levels were 50 ± 5.1p˚ amol/L in wildtype
animals and 46 ± 4.9pmol/L in transgenic mice (NS).
The insulin response to protein ingestion was impaired in
transgenic mice; the suprabasal AUC for insulin for the 120-
minute study period was 27.2 ± 3.1nmol/L × 120 minutes
in wildtype animals versus 16.5 ± 3.9nmol/L × 120 minutes
in transgenic animals (P = .018) (Figure 1, upper right).
Baseline glucose levels were 7.2 ± 0.3mmol/L in wildtype
animals and 7.8 ± 0.2mmol/L in transgenic mice (NS);
glucose levels did not change signiﬁcantly during the test
(Figure 1, lower left panel).
3.3. Acetaminophenresponsetoacetaminophen
administration
Figure 1 (lower right) shows the acetaminophen concen-
trations during test. Plasma acetaminophen increased to a
maximumlevelat15minutesafteradministration,thereafter
it gradually fell. There was no signiﬁcant diﬀerence between
the groups in plasma acetaminophen.
4. DISCUSSION
This study evaluated the islet hormone responses to oral
protein ingestion in mice with β-cell speciﬁc overexpression
of human IAPP. It was found that the insulin response to
protein was impaired in transgenic mice. This conﬁrms that
these mice have impaired insulin secretion, as previously
was reported also after oral glucose challenge [15]. The
main novel ﬁnding in this report is, however, that the
transgenic mice have also changes in the glucagon levels.
Thus, the mice were found to have higher baseline glucagon
levels than their wildtype counterparts and yet they have a
reduced glucagon response to protein administration. The
mechanism of the high-baseline glucagon remains to be
established. It is, however, consistent with the disturbance
in islet topography in these mice. Thus, we have previously
shown that the islets of these mice have enlarged population
of glucagon producing α c e l l sa so p p o s e dt ot h er e d u c e d
β-cell immunostaining in these animals which is associatedB. Ahr´ en and M. S¨ orhede Winzell 3
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Figure 1: Plasma levels of glucagon, insulin, glucose, and acetaminophen following administration of whey protein (75mg) and
acetaminophen (2mg) in female wildtype mice (n = 5) and transgenic mice with β-cell speciﬁc overexpression of hIAPP (n = 6).
Means±SEM are shown. Asterisks indicate probability level of random diﬀerence between the two groups (∗P<. 05).
with signiﬁcantly reduced islet insulin content [16]. This
hyperglucagonemia may be the result of the reduced islet
insulin, in view of the inhibitory inﬂuence of insulin on
glucagon secretion. At the same time, the glucagon response
to the protein administration was impaired, which may
be explained by the transgene, because IAPP is known
to inhibit glucagon secretion [8–11]. Hence, high-baseline
glucagon and impaired glucagon response to stimulation are
two characteristics of the hIAPP transgene, and may have
diﬀerent mechanisms.
In this study, we also determined the acetaminophen
concentration after acetaminophen administration to deter-
mine whether gastric emptying had been altered in the
transgenic mice. Previously, inhibition by IAPP of gastric
emptying has been demonstrated [11] and changes in gastric
emptying would be a mechanism for changes in glucagon
secretion after protein administration. The acetaminophen
test has previously been validated in humans [20]a n d
used in a previous study in mice [17]. It is based on the
poor absorption of acetaminophen from the stomach and
the rapid and almost complete absorption from the small
intestine. This implies that plasma acetaminophen proﬁles
give an estimation of gastric emptying, which also has
been veriﬁed as good correlation with isotopic technique
measurements of gastric emptying [21, 22]. We found that
there was no diﬀerence in plasma acetaminophen proﬁles
between transgenic and wildtype mice. This shows that the
increase in β-cell IAPP expression does not aﬀect gastric4 Experimental Diabetes Research
emptying, and, therefore, the inhibited glucagon response
to oral protein in these mice is not due to impaired gastric
emptying.
In conclusion, this study has shown that β-cell speciﬁc
overexpression of human IAPP increases baseline glucagon
levels and impairs the glucagon response to oral protein
in association with impaired insulin response. This shows
that a disturbed α-cell function in these mice is evident in
association with the previously described disturbed β-cell
function [15, 16].
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